Evidence map›Paper›PMID 38492156›Full record

ArticleJournal of assisted reproduction and genetics2024

Is there a preferred time interval between gonadotropin-releasing hormone (GnRH) agonist trigger and oocyte retrieval in GnRH antagonist cycles? A retrospective cohort of planned fertility preservation cycles.

Hizkiyahu Ranit, Herzberg Shmuel, Athavale Ahlad, Greenbaum Shirley, Harari Meny, Imbar Tal, Ben-Meir Assaf, Adler Lazarovits Chana, Bentov Yaakov, Esh-Broder Efrat and 1 more

Abstract read
In one paragraph

Article in Journal of assisted reproduction and genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. The Trigger in IVF Cycles: Molecular Pathways and Clinical Implications.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hizkiyahu Ranit *The IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel. ranithizk@gmail.com.ORCID http://orcid.org/0000-0002-1466-7178
Herzberg Shmuel *The IVF unit, Department of Obstetrics and Gynecology, Hadassah Ein Kerem-Hebrew University Medical Center, Jerusalem, Israel.
Athavale AhladThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel.
Greenbaum ShirleyThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel.
Harari MenyFaculty of medicine, Hebrew university of Jerusalem, Jerusalem, Israel.
Imbar TalThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Ein Kerem-Hebrew University Medical Center, Jerusalem, Israel.
Ben-Meir AssafThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Ein Kerem-Hebrew University Medical Center, Jerusalem, Israel.
Adler Lazarovits ChanaThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel.
Bentov YaakovThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel.
Esh-Broder EfratThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel.
Hershko Klement AnatThe IVF unit, Department of Obstetrics and Gynecology, Hadassah Mount Scopus-Hebrew University Medical Center, Jerusalem, 9112001, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ideal time frame between gonadotropin-releasing hormone (GnRH) agonist (GnRHa) trigger administration and oocyte retrieval in GnRH antagonist cycles has not been well studied. Our goal was to evaluate the effect of this time interval on oocyte yield and oocyte maturation rate in GnRH antagonist cycles designated for non-medical ("planned") oocyte cryopreservation.

methodsWe conducted a retrospective cohort study including patients who underwent elective fertility preservation, using the GnRH antagonist protocol and exclusively triggered by GnRH-agonist. We focused on the effect of the trigger-to-retrieval time interval on oocyte yield and maturation rate, while also incorporating age, body mass index (BMI), anti-Müllerian hormone (AMH) levels, basal Follicle-Stimulating Hormone (FSH) levels, as well as the type and dosage of gonadotropin FSH medication.

results438 cycles were included. Trigger-to-retrieval time interval ranged from 32.03 to 39.92 h. The mean oocyte yield showed no statistically significant difference when comparing retrievals < 36 h (n = 240, 11.86 ± 8.6) to those triggered at ≥ 36 h (n = 198, 12.24 ± 7.73) (P = 0.6). Upon dividing the cohort into four-time quartiles, no significant differences in the number of retrieved oocytes were observed (P = 0.54). Multivariate regression analysis failed to reveal any significant associations between the interval and the aforementioned variables.

conclusionsThe GnRHa trigger to oocyte retrieval interval range in our cohort did not significantly affect oocyte yield and maturation rate.

Indexed as

CryopreservationFertility PreservationGonadotropin-Releasing HormoneOocyte RetrievalOocytesOvulation InductionAdultAnti-Mullerian HormoneFemaleFertilization in VitroFollicle Stimulating HormoneHormone AntagonistsHumansPregnancyPregnancy RateRetrospective StudiesAnti-Mullerian HormoneFollicle Stimulating HormoneGonadotropin-Releasing HormoneHormone AntagonistsEgg freezingGonadotropin releasing hormoneHormone antagonistOocyte retrievalOperative timeOvulation

Identifiers

PMID38492156
PMCPMC11224053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.